Summary 5F-AMB, also recognized as 5F-MMB-PINACA and 5F-AMB-PINACA, belongs to the indazole-3-carboxamide family, making it a synthetic cannabinoid of this class. It has been employed as an active constituent in synthetic cannabis products and was initially pinpointed in Japan in the early months of 2014. While there is limited pharmacological data available specifically for 5F-AMB …
Summary 5F-ADB, also known as 5F-MDMB-PINACA, falls within the indazole-3-carboxamide family, making it a synthetic cannabinoid of this class. It has been actively utilized as a key component in synthetic cannabis products and has been marketed online as a designer drug. This compound exerts a potent agonistic effect on the CB1 receptor, although its selectivity …
Summary 5F-ADB-PINACA, a synthetic cannabinoid designer drug found in certain synthetic cannabis blends, exhibits significant agonistic activity towards both the CB1 and CB2 receptors, boasting low EC50 values of 0.24 nM and 2.1 nM, respectively. Identifiers IUPAC name CAS Number 1863065-90-0 PubChem CID 119058050 ChemSpider 52085408 UNII LOL2KQM530 Chemical and physical data Formula C19H27FN4O2 Molar …
Summary 5F-AB-PINACA is an indazole-derived synthetic cannabinoid originating from a group of compounds initially created by Pfizer in 2009 for pain relief. This substance has gained notoriety as a designer drug available for purchase online.In research, 5F-AB-PINACA has demonstrated notable potency as an agonist, affecting both the CB1 receptor and CB2 receptor, with EC50 values …
Summary 4F-MDMB-BINACA, also recognized as 4F-MDMB-BUTINACA or 4F-ADB, belongs to the indazole-3-carboxamide family, making it an indazole-based synthetic cannabinoid. It has been prevalent as an active component in synthetic cannabis products and has been accessible as a designer drug since late 2018. 4F-MDMB-BINACA acts as an agonist of the CB1 receptor (with an EC50 of …
Sumamry WIN 55,212-2, classified as an aminoalkylindole derivative, exerts effects akin to cannabinoids such as tetrahydrocannabinol (THC) but boasts a distinctly unique chemical structure.Functionally, WIN 55,212-2 acts as a robust cannabinoid receptor agonist,[6] demonstrating potent analgesic properties in a rat model of neuropathic pain, activating p42 and p44 MAP kinase through receptor-mediated signaling.At a concentration …
Summary QMPSB, initially identified as an aryl sulfonamide-based synthetic cannabinoid, found its place in the realm of designer drugs.In 2007, Nathalie Lambeng and her research team unearthed QMPSB, unveiling its role as a robust full agonist of the CB1 and CB2 receptors, boasting impressive Ki values of 3 nM and 4 nM, respectively. Following this …
Summary NESS-040C5, designed for glaucoma treatment, is a robust cannabinoid agonist. It demonstrates a notable preference for the CB2 receptor subtype, boasting a remarkable CB2 affinity at 0.4 nanomolar and a selectivity exceeding 25-fold when compared to the closely related CB1 receptor. Identifiers IUPAC name CAS Number 1445751-90-5 PubChem CID 138402821 UNII P6H2AAY2GE CompTox Dashboard …
Summary NESS-0327 is a pharmaceutical substance utilized in scientific investigations, recognized for its remarkable role as a highly potent and exceedingly selective antagonist of the cannabinoid receptor CB1. Its antagonistic potency greatly surpasses the more commonly employed ligand, rimonabant. With an astounding Ki at CB1 measuring a mere 350 femtomolar (0.00035 nanomolar), NESS-0327 exhibits an …
Summary MDA-19 also recognized as BZO-HEXOXIZID, is a potent and highly selective agonist specifically designed for the cannabinoid receptor CB2. It maintains reasonable selectivity over the psychoactive CB1 receptor, although variations are observed among different species. In animal studies, MDA-19 has shown effectiveness in addressing neuropathic pain, with no significant impact on rat locomotor activity …
